Safety, Tolerability, and Pharmacokinetics of AN01 Inhalation Powder in Healthy Participants

Phase 1, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing AN01 with Placebo (2 arms). Primary endpoints: Incidence, severity, relationship to the investigational drug, and types of adverse events and serious adverse events, Number of participants with abnormal clinically significant physical examination (PE) results and 5 more. Started May 2026; status: completed.